… cases occurring in patients who use immunomodulatory therapy and to describe their …
requested reports of COVID-19 cases among patients receiving immunomodulatory therapy. Two …

… the early initiation of additional immune therapy. Possible new targets … and therapy regimens
among patients with COVID-19, … shown with an immunosuppressive therapy in small patient …

… Severe COVID-19 was defined by a 3-level variable: mild … and MS therapies associated
with severe COVID-19 by … of immunomodulatory and immunosuppressive therapies in …

… immunomodulation in patients with escalating oxygen requirement. This also represents our
common practice to consider immunomodulation in a subset of severe Covid-19 patients in …

… clinical outcomes in COVID-19 in … immunomodulatory therapy. Our findings provide early
insights into molecular signatures that correlate with immunomodulatory therapies in COVID-19 …

… knowledge on the emerging role of mesenchymal stem cell in our fight against COVID-19,
and will have implications on developing innovative therapies for COVID-19 infected patients …

… To date, there is no proven effective drug or immunomodulator therapy for the management
of COVID-19. As this SARS-CoV-2 pandemic escalates, the search for an effective treatment …

… In this analysis, 10.5% of global COVID-19 clinical trials are testing combination therapies,
with the … drug classes such as antivirals and anti-inflammatory/immunomodulatory therapies. …

… of immunomodulatory therapies on vaccine efficacy. Clinical residual samples were used for
the assessment of the COVID-19 … interaction between immunomodulatory therapies and the …

… to rank immunomodulators in the treatment of COVID-19 … immunomodulators for the treatment
of COVID-19 are lacking. We aim to rank immunomodulators in the treatment of COVID-19 …